Sept 19 (Reuters) - Medical device maker Axonics has convinced a jury in California federal court that it did not violate rival Medtronic's (MDT.N), opens new tab patent rights in nerve-stimulation ...
Axonics, Inc. AXNX has received regulatory approval from the Therapeutic Goods Administration (TGA) to market its R20 rechargeable sacral neuromodulation (SNM) system in Australia. This cutting-edge ...
IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that it has received regulatory approval from the Therapeutic Goods Administration (TGA) for marketing the Axonics F15™ ...
Boston Scientific is taking clear steps to advance its European, Middle East and Africa (EMEA) region market position in the ...
Axonics devices are implanted to help control incontinence and can last as long as 17 to 24 years or more Boston Scientific Corp. (NYSE: BSX) announced that it has closed on its acquisition of ...
Weighted-average shares used to compute basic and diluted net loss per share ...
Axonics Inc. will soon make its television debut in an ad campaign about its therapies to treat bowel and urinary incontinence, company executives say. According to Axonics CEO Raymond Cohen, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results